Sigma Of Australia Offers To Work With Suitor Aspen After Lower Bid
This article was originally published in PharmAsia News
Executive SummaryAustralia's Sigma Pharmaceuticals says it plans to work with Aspen Pharmacare of South Africa to get a better buyout bid for the ailing company
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.